home / stock / qure / qure quote
Last: | $3.91 |
---|---|
Change Percent: | 0.0% |
Open: | $4.01 |
Close: | $3.91 |
High: | $4.0799 |
Low: | $3.9 |
Volume: | 585,757 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.91 | $4.01 | $3.91 | $4.0799 | $3.9 | 585,757 | 07-03-2024 |
$4.01 | $4.43 | $4.01 | $4.43 | $3.94 | 1,124,365 | 07-02-2024 |
$4.445 | $4.44 | $4.445 | $4.58 | $4.375 | 463,764 | 07-01-2024 |
$4.48 | $4.5 | $4.48 | $4.58 | $4.31 | 435,444 | 06-28-2024 |
$4.54 | $4.43 | $4.54 | $4.56 | $4.32 | 372,573 | 06-27-2024 |
$4.4 | $4.49 | $4.4 | $4.49 | $4.365 | 504,285 | 06-26-2024 |
$4.46 | $4.5 | $4.46 | $4.54 | $4.43 | 394,192 | 06-25-2024 |
$4.54 | $4.55 | $4.54 | $4.62 | $4.38 | 469,463 | 06-24-2024 |
$4.59 | $4.6 | $4.59 | $4.78 | $4.53 | 459,197 | 06-21-2024 |
$4.56 | $4.51 | $4.56 | $4.6 | $4.42 | 431,020 | 06-20-2024 |
$4.57 | $4.65 | $4.57 | $4.67 | $4.515 | 609,003 | 06-19-2024 |
$4.57 | $4.65 | $4.57 | $4.67 | $4.515 | 609,003 | 06-18-2024 |
$4.69 | $4.89 | $4.69 | $4.89 | $4.65 | 607,368 | 06-17-2024 |
$4.89 | $5.2 | $4.89 | $5.2 | $4.86 | 541,461 | 06-14-2024 |
$5.25 | $5.26 | $5.25 | $5.34 | $5.2 | 318,867 | 06-13-2024 |
$5.28 | $5.41 | $5.28 | $5.49 | $5.205 | 376,016 | 06-12-2024 |
$5.23 | $5.33 | $5.23 | $5.36 | $5.07 | 524,896 | 06-11-2024 |
$5.38 | $5.28 | $5.38 | $5.43 | $5.182 | 414,433 | 06-10-2024 |
$5.33 | $5.23 | $5.33 | $5.35 | $5.15 | 451,721 | 06-07-2024 |
$5.31 | $5.44 | $5.31 | $5.44 | $5.29 | 324,131 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA PR Newswire Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. ...
~ Proposed divestiture streamlines uniQure’s focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~ ~ Genezen to manufacture global commercial supply of HEMGENIX ® and support uniQure’s pipeline progr...
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s disease ~ ~ Receiving RMAT designation enables increased collaboration with ...